IL6 and Respiratory distress: The sensitivity to IL-6 concentration before AST-monitored organ damage suggests anti-IL-6 therapeutics could be an effective tool for management in the early and rapidly progressive stages of respiratory distress for αEp9-positive patients (31, 37, –, 41).